Dr. Mahal on the Emerging Role of Epigenomics in Prostate Cancer

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the emerging role of epigenomics in prostate cancer.

Ongoing research in the field of epigenomics has garnered significant attention in prostate cancer, says Mahal.

Developing a greater understanding of the molecular characteristics of prostate cancer may lend insight into drivers of prostate cancer and disease aggressiveness, Mahal explains.

Moreover, epigenetics may inform the influence the environment has on a patient’s genome and on disparities between patient subgroups with prostate cancer, concludes Mahal.